Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

595 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates.
Haddox CL, Nathenson MJ, Mazzola E, Lin JR, Baginska J, Nau A, Weirather JL, Choy E, Marino-Enriquez A, Morgan JA, Cote GM, Merriam P, Wagner AJ, Sorger PK, Santagata S, George S. Haddox CL, et al. Among authors: choy e. Clin Cancer Res. 2024 Apr 1;30(7):1281-1292. doi: 10.1158/1078-0432.CCR-23-2250. Clin Cancer Res. 2024. PMID: 38236580 Free PMC article. Clinical Trial.
Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial.
Wagner AJ, Goldberg JM, Dubois SG, Choy E, Rosen L, Pappo A, Geller J, Judson I, Hogg D, Senzer N, Davis IJ, Chai F, Waghorne C, Schwartz B, Demetri GD. Wagner AJ, et al. Among authors: choy e. Cancer. 2012 Dec 1;118(23):5894-902. doi: 10.1002/cncr.27582. Epub 2012 May 17. Cancer. 2012. PMID: 22605650 Free article. Clinical Trial.
Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
George S, Wang Q, Heinrich MC, Corless CL, Zhu M, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Yap JT, Van den Abbeele AD, Manola JB, Solomon SM, Fletcher JA, von Mehren M, Demetri GD. George S, et al. Among authors: choy e. J Clin Oncol. 2012 Jul 1;30(19):2401-7. doi: 10.1200/JCO.2011.39.9394. Epub 2012 May 21. J Clin Oncol. 2012. PMID: 22614970 Free PMC article. Clinical Trial.
Update in treatment and targets in Ewing sarcoma.
Cote GM, Choy E. Cote GM, et al. Among authors: choy e. Hematol Oncol Clin North Am. 2013 Oct;27(5):1007-19. doi: 10.1016/j.hoc.2013.07.001. Epub 2013 Aug 3. Hematol Oncol Clin North Am. 2013. PMID: 24093173 Review.
Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib.
Shinagare AB, Jagannathan JP, Kurra V, Urban T, Manola J, Choy E, Demetri GD, George S, Ramaiya NH. Shinagare AB, et al. Among authors: choy e. Eur J Cancer. 2014 Mar;50(5):981-6. doi: 10.1016/j.ejca.2013.11.037. Epub 2014 Jan 2. Eur J Cancer. 2014. PMID: 24388774 Free PMC article. Clinical Trial.
Prognostic significance of miRNA-1 (miR-1) expression in patients with chordoma.
Duan Z, Shen J, Yang X, Yang P, Osaka E, Choy E, Cote G, Harmon D, Zhang Y, Nielsen GP, Spentzos D, Mankin H, Hornicek F. Duan Z, et al. Among authors: choy e. J Orthop Res. 2014 May;32(5):695-701. doi: 10.1002/jor.22589. Epub 2014 Feb 5. J Orthop Res. 2014. PMID: 24501096 Free PMC article.
595 results